Corey Langer, MD
Enriched profileDirector of Thoracic Oncology and Professor of Medicine (Hematology-Oncology), Hospital of the University of Pennsylvania · University of Pennsylvania
Corey Langer is Director of Thoracic Oncology and Professor of Medicine (Hematology-Oncology), Hospital of the University of Pennsylvania at University of Pennsylvania. OpenAlex indexes 865 publications with 40,136 citations (h-index 90); ClinicalTrials.gov lists 25 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Hematology / Oncology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Corey Langer, MD, is Director of Thoracic Oncology and Professor of Medicine (Hematology-Oncology), Hospital of the University of Pennsylvania at University of Pennsylvania – Perelman School of Medicine / Abramson Cancer Center. The public record shows 865 publications with 40,136 citations (h-index 90), centered on Lung Cancer Treatments and Mutations, Lung Cancer Diagnosis and Treatment, Lung Cancer Research Studies. It also documents an investigator role on 25 registered clinical trials, industry payments reported by 38 companies.
- Most recent indexed publication: 2024 · The oncologist
- Top research focus: Lung Cancer Treatments and Mutations
- 25 registered trials on ClinicalTrials.gov
- Open Payments reporting from 38 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 6 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 337.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 25 registered studies on ClinicalTrials.gov. The most recent:
- Predictive Assay for Decision Making in Adjuvant Therapy
Sponsor: Insight Molecular Diagnostics
- Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Sponsor: SWOG Cancer Research Network
- Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)
Sponsor: Abramson Cancer Center at Penn Medicine
Industry payments
Updated 27 Aug 2026
38 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year202521 payments$29,141openpaymentsdata.cms.gov ↗
- AstraZeneca Pharmaceuticals LPProgram year20253 payments
- Janssen Research & Development, LLCProgram year20254 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
41.3%Corticosteroid32.6%Prednisone100%Part D≥37 patientsSerotonin-3 Receptor Antagonist8.7%Ondansetron Hcl100%Part D≥12 patientsAnti-infectives
19.3%Macrolide Antimicrobial11.5%Azithromycin100%Part D≥21 patientsPenicillins with extended spectrum7.8%Amoxicillin-Clavulanate Potass100%Part D≥15 patientsSensory organs
12.4%Corticosteroid12.4%Dexamethasone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 27 Aug 2026
192 congress contributions (2003–2025) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:
- EMBER-Lung: Electronic medical record boosting molecular testing in early stage NSCLC.
ASCO Annual Meeting
ASCO2025Co-author - Survival after osimertinib dose-reduction, discontinuation in 1L <i>EGFR</i> -mutated metastatic non-small cell lung cancer (mNSCLC).
ASCO Annual Meeting
ASCO2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patients.
Science (New York, N.Y.)
Clinical Trial2024
Most-cited works
by citation count (OpenAlex)- 01Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung CancerArticle4,994 citations2002
- 02CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatmentArticle2,579 citations2003
- 03
- 04
- 05
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/corey-langer-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
iaslc.org/iaslc-news/lung-cancer-considered/conversation-thoracic-oncologist-dr-corey-langer
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →iaslc.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pennmedicine.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pennmedicine.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pennmedicine.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.upenn.edu ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ilcn.org ↗
- Fellow
American College of Physicians (FACP)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ilcn.org ↗ - Member
HUP Pharmacy and Therapeutics Committee
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.upenn.edu ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →almanac.upenn.edu ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mesotheliomahope.com ↗
Secondary affiliations
appointments beyond the home institution- Director
Penn Lung Cancer Program, Penn Mesothelioma Program, and Penn Pleural Disease Program
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pennmedicine.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pennmedicine.org ↗
Media & interviews
press, podcasts and appearances- Regular expert contributor
'Lung Cancer Update' podcast (Research To Practice)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →podcasts.apple.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →iaslc.org ↗
- Panelist
World Lung Cancer Day livestream discussion, Oncology Data Advisor
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncdata.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Carl June, MD
University of Pennsylvania
Harold Feldman, MD
University of Pennsylvania
Howard Herrmann, MD
University of Pennsylvania
Robert Vonderheide, MD
University of Pennsylvania